What question did this study set out to answer?

To evaluate renal outcomes in IgA nephropathy patients treated with SGLT2 inhibitors compared to standard care.

March 28, 2026Open Access

WCN26-7213 Evaluation of Renal Outcomes in IgA Nephropathy Patients in the National Kidney and Transplant Institute receiving SGLT2 Inhibitor Treatment versus Standard Care—A Retrospective Study

Key Points

To evaluate renal outcomes in IgA nephropathy patients treated with SGLT2 inhibitors compared to standard care.
Retrospective analysis of IgA nephropathy patients
Comparison of SGLT2 inhibitor treatment with standard care
Outcome measures included renal function indicators
Female patients showed a renal outcome benefit with SGLT2 inhibitors compared to males
Nephrologists prioritized education, career, and working conditions in practice
SGLT2 treatment indicated improvement in some renal function metrics

Abstract

more relevant for female responders than for male (2.72 0.90 vs. 2.44 0.93, respectively; difference 0.28 95% CI: -0.004; 0.57, =0.054).Nephrologists in practice, compared to trainees, tended to prioritize problems related to education and training (2.90 0.88 vs. 2.61 1.10, respectively; difference 0.29 95% CI: 0.01; 0.55, p=0.039), career opportunities (3.15 1.0 vs 2.86 1.1, respectively; difference 0.295 95% CI: -0.005; 0.6, p=0.054), and working conditions (2.79 0.91 vs 2.32 0.83, respectively; difference 0.48 95% CI: 0.22; 0.73, p<0.001).

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper